August 3, 2026

2026 Second Quarter Financial Results

Redefining Possibilities in Rare Disease

Jazz Pharmaceuticals

Transforming Lives. Redefining Possibilities.

Caution Concerning Forward-Looking Statements

This presentation contains forward-looking statements, including, but not limited to, statements related to: sales growth for the company's combined rare oncology and epilepsy franchises in 2026, Xywav sales in 2026 and rare sleep revenue in 2026; the company's growth prospects and future financial and operating results, including the company's 2026 financial guidance and the company's expectations related thereto; the company's advancement of pipeline programs and the timing of development activities, regulatory activities, approvals, and submissions related thereto; the potential for a near-term commercial launch of zanidatamab in 1L HER2+ GEA in the U.S., if approved; planned or anticipated clinical trial events, including with respect to initiations, enrollment and data read-outs, and the anticipated timing thereof, including: the second interim OS data from the Phase 3 HERIZON trial of zanidatamab in 1L GEA, the top-line data from the EmpoweHER-BC-303 trial in breast cancer and top-line data from the Phase 3 ACTION trial of Modeyso in recurrent H3 K27M-mutant diffuse glioma; and the company's development, regulatory and commercialization strategy; the company's expectations with respect to its regulatory submissions, including its NDA for a cannabidiol oral capsule formulation for potential use in existing approved Epidiolex/Epidyolex formulations; the company's expectations with respect to its products and product candidates and the potential of the company's products and product candidates and the potential regulatory path related thereto, including zanidatamab's potential to become the HER2-targeted therapy of choice in 1L HER2+ GEA, regardless of PD-L1 status; the company's capital allocation and corporate development strategy; the potential successful future development, manufacturing, regulatory and commercialization activities; the company's expectations with respect to its collaborations with third parties, including its collaboration with AbCellera; the company's ability to realize the commercial potential of its products; the company's net product sales and goals for net product sales from new and acquired products; the company's views and expectations relating to its patent portfolio, including with respect to expected patent protection, as well as expectations with respect to exclusivity; the company's clinical trials confirming clinical benefit or enabling regulatory submissions, including the potential of the ongoing Phase 3 ACTION trial to confirm clinical benefit of Modeyso in recurrent H3 K27M-mutant diffuse glioma and extend to use in 1L patients; and other statements that are not historical facts. These forward-looking statements are based on the company's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties.

Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: maintaining or increasing sales of, and revenue from, Xywav, Epidiolex/ Epidyolex, Ziihera, Modeyso, Zepzelca and other lead marketed products; effectively launching and commercializing the company's other products and product candidates, including zanidatamab in 1L HER2+ GEA, if approved; the successful completion of development and regulatory activities with respect to the company's product candidates; obtaining and maintaining adequate coverage and reimbursement for the company's products; the time-consuming and uncertain regulatory approval process, including the risk that the company's current and/or planned regulatory submissions may not be submitted, accepted or approved by applicable regulatory authorities in a timely manner or at all, including the risk that the zanidatamab in 1L HER2+ GEA may not be approved in a timely manner or at all; the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients; global economic, financial, and healthcare system disruptions and the current and potential future negative impacts to the company's business operations and financial results; protecting and enhancing the company's intellectual property rights and the company's commercial success being dependent upon the company obtaining, maintaining and defending intellectual property protection and exclusivity for its products and product candidates; delays or problems in the supply or manufacture of the company's products and product candidates, including due to geopolitical tensions and military conflicts; complying with applicable U.S. and non-U.S. regulatory requirements, including those governing the research, development, manufacturing and distribution of controlled substances; government investigations, legal proceedings and other actions; identifying and consummating corporate development transactions, financing these transactions and successfully integrating acquired products, product candidates and businesses; the company's ability to realize the anticipated benefits of its collaborations and license agreements with third parties; the sufficiency of the company's cash flows and capital resources; the company's ability to achieve targeted or expected future financial performance and results and the uncertainty of future tax, accounting and other provisions and estimates; fluctuations in the market price and trading volume of the company's ordinary shares; and other risks and uncertainties affecting the company, including those described from time to time under the caption "Risk Factors" and elsewhere in the company's Securities and Exchange Commission filings and reports, including the company's Annual Report on Form 10-K for the year ended December 31, 2025 and future filings and reports by the company. Other risks and uncertainties of which the company is not currently aware may also affect the company's forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated.

Transforming Lives. Redefining Possibilities.

Non-GAAP Financial Measures

To supplement Jazz Pharmaceuticals' financial results and guidance presented in accordance with U.S. GAAP, the company uses certain non-GAAP (also referred to as adjusted or non-GAAP adjusted) financial measures in this presentation. The company presents non-GAAP ANI (ANL) (and the related per share measure) and certain line item components as well as certain non-GAAP adjusted financial measures derived therefrom, including non-GAAP adjusted gross margin percentage and non-GAAP adjusted effective tax rate. Non-GAAP ANI (ANL) (and the related per share measure) and its line item components exclude from GAAP reported net income (loss) (and the related per share measure) and its line item components certain items, as detailed in the reconciliation tables that follow in the Appendix hereto, and in the case of non-GAAP ANI (ANL) (and the related per share measure), adjust for the income tax effect of the non-GAAP adjustments. In this regard, the components of non-GAAP ANI (ANL), including non-GAAP adjusted cost of product sales, SG&A expenses and R&D expenses, are income statement line items prepared on the same basis as, and therefore components of, the overall non-GAAP ANI (ANL) measure.

The company believes that each of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors and analysts and that each of these non-GAAP financial measures, when considered together with the company's financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare the company's results from period to period and to its forward-looking guidance, and to identify operating trends in the company's business. In addition, these non-GAAP financial measures are regularly used by investors and analysts to model and track the company's financial performance. The company's management also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate the company's business and to make operating decisions, and compensation of executives is based in part on certain of these non-GAAP financial measures. Because these non-GAAP financial measures are important internal measurements for the company's management, the company also believes that these non-GAAP financial measures are useful to investors and analysts since these measures allow for greater transparency with respect to key financial metrics the company uses in assessing its own operating performance and making operating decisions. These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the company's consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles in the reconciliation tables that follow. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its non-GAAP financial measures; and the company has ceased, and may in the future cease, to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. Likewise, the company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by the company in this presentation and the accompanying tables have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.

Introduction and Overview

Renee Gala
President and Chief Executive Officer

Jazz Pharmaceuticals

Strong Execution Across Franchises Drives 2026 Revenue Guidance Increase

2Q26 Execution Highlights

Commercial:

- **Xywav** (+13% YoY)
- **Epidiolex** (+16% YoY)
- **Zepzelca** (+42% YoY)
- **Prepared to launch** zanidatamab in HER2+ 1L GEA

R&D:

- Phase 3 HERIZON-GEA-01 data published in ***The New England Journal of Medicine***[1]
- **Submitted NDA** for cannabidiol capsule formulation[2]
- Announced collaboration with AbCellera to discover **next-generation TCE multispecific antibodies**

Financial Strength

Robust 2Q26:

- **Record quarterly revenues of $1.2B** (+16% YoY)
- **Double-digit growth**[3] from sleep, epilepsy and oncology franchises
- **Raised** full-year 2026 **revenue guidance**

Strong balance sheet:

- Cash[4] at end of 2Q26: **$2.2B**
- YTD[5] operating cash flow: **$824M**

Upcoming Milestones

- **Ready to launch** zanidatamab in GEA; PDUFA date of August 25, 2026
- HERIZON-GEA-01 **interim OS data**[6] 3Q26
- Modeyso **ACTION study** data 1H27
- EmpowHER-BC-303 trial enrolling, **data expected** late 2027 / early 2028
- Zanidatamab development program **continues to progress**
- Opportunity for additional **business development** in rare disease

[1]Shitara et al., The New England Journal of Medicine, May 2026; [2]Cannabidiol capsule formulation, if approved, for use within Epidiolex's existing approved indications (LGS, DS or TSC); [3]Double-digit growth based on net product sales, which excludes revenues from high-sodium AG royalties; [4]Cash includes cash, equivalents, and investments as of June 30, 2026; [5]For the six months ended June 30, 2026; [6]Top-line results from the second interim survival analysis for the HERIZON-GEA-01 doublet regimen of zanidatamab + chemotherapy.

Commercial Performance

Sam Pearce
Executive Vice President and
Chief Commercial Officer

Jazz Pharmaceuticals

Xywav: Differentiated by Low Sodium; IH Provides Growth Opportunity



xywav™

- Xywav revenue **grew 13% YoY** in 2Q26; **continued momentum with 525 net patient adds** in 2Q26
- Benefits of **highly efficacious and safer** treatment option due to **reduced sodium content along with** an **individualized dosing regimen** continue to resonate with patients and HCPs

Narcolepsy

- Xywav remains the **#1 branded treatment** for narcolepsy[2]

Idiopathic Hypersomnia

- Continued **positive momentum** from investments to further build the IH market driving **325 IH net patient adds** in 2Q26

Rare sleep[3] franchise:

- Total rare sleep[3] revenue of **$544 million** in 2Q26
- In 2026, expect total rare sleep[3] revenue of **$2.025 to $2.125 billion**

[1]Approximate active Xywav patients exiting quarter; [2]Based on 2Q26 Xywav net product sales; [3]Rare Sleep franchise consists of Xywav, Xyrem and high-sodium oxybate AG royalties.

Epidiolex: Development Opportunities for Durable Growth



Epidiolex®

Epidyolex® cannabidiol Oral solution

Epidiolex is the #1 branded epilepsy treatment[1]

- Continued **commercial momentum with $292M** in 2Q26 revenue

Growth opportunities:

- **Expanded Epidiolex development opportunities** with multiple new clinical trials
- Submitted NDA for **cannabidiol capsule formulation**[2] to help broaden utilization and increase flexibility for patients
- **Further data generation**, including **beyond-seizure benefits** from the EpiCom[3] study in TSC and nurse-reported responses the BECOME[4] caregiver survey in long-term care facilities
- **JazzCares** suite of services including the **Nurse Navigator program** helps support patients and families through their treatment journey

[1]Based on 2Q26 Epidiolex net product sales; [2]Cannabidiol capsule formulation, if approved, for use in Epidiolex's currently approved indications: LGS, DS, TSC; [3]Eeghen, AM, Thiele, EA, et al. Poster presented at: American Epilepsy Society 2024 Annual Meeting, December 6-10, 2024. Los Angeles, CA; [4]Wrobel, N. Poster presented at: American Academy of Neurology 2025 Annual Meeting, April 5-9. San Diego, CA.

Zanidatamab: De-Risked Near-Term Opportunity

Goal to be the HER2-targeted agent of choice

- Ready to launch in 1L GEA on or before PDUFA date of August 25, 2026
- Customer-facing team in place and prepared for launch

Biliary Tract Cancer

ZIIHERA® zanidatamab

Standard of care in 2L HER2+ BTC

1L HER2+ BTC **confirmatory trial ongoing**

Granted **conditional marketing** authorization by EC in 2L HER2+ BTC for monotherapy treatment

~12,000
BTC cases annually[1] in U.S., Europe[2] and Japan

Gastroesophageal Adenocarcinoma

FDA granted Breakthrough Therapy designation for patients with 1L HER2+ GEA

Ready to launch in GEA

Potential to become the **new standard of care** for patients with 1L **HER2+ GEA regardless of PD-L1 status**

Opportunity to **explore potential in neoadjuvant** populations[3]

~63,000
GEA cases annually[1] in U.S., Europe[2] and Japan

Breast Cancer

Expanded opportunity across lines of therapy[3]:
- Post T-DXd (Ph 3 EmpowHER-BC-303 trial)
- Early BC (Ph 2 EmpowHER-BC-208 trial)
- Novel combinations (collaborations with novel TKIs from Boeringher Ingelheim and Iambic)

Potential for **novel chemo-free regimen** for **HER2+/HR+** patients[3]

Ongoing collaborations in early breast cancer:
- I-SPY2 Trial[4]
- MD Anderson collaboration

~150,000
BC cases annually[5] in U.S., Europe[2] and Japan

Other HER2-Expressing Cancers

Broad potential beyond BTC, GEA and BC in multiple HER2-expressing indications **based on compelling clinical activity from early trials**[6]:
- Colorectal (Received BTD)
- NSCLC
- Ovarian
- Endometrial
- Pancreatic
- Bladder
- Salivary Gland
- Ampullary
- Other HER2-expressing solid tumors

Ongoing Phase 2 DiscovHER-Pan-206
- Zanidatamab monotherapy in previously-treated patients with no available treatment options

Broad Potential
Beyond BTC, GEA, and BC

[1]Incidence sources: Kantar reports, ToGA surveillance report; SEER, cancer.gov; ClearView Analysis; GLOBOCAN, Data on file; [2]Major markets, U.K, France, Germany, Spain, Italy; [3]Pending regulatory approvals; [4]NCT01042379, in collaboration with QuantumLeap Healthcare Collaborative; [5]Incidence source estimates derived from multiple sources: Decision Resources Group, Kantar Health, Jazz Market Research, data on file; [6]Funda Meric-Bernstam et al, Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study, The Lancet Oncology, Volume 23, Issue 12, 2022, Pages 1558-1570, ISSN 1470-2045, https://doi.org/10.1016/S1470-2045(22)00621-0.

Ready for GEA Launch
Focus Areas at Launch

1. Clinical Education & Differentiation

Establishing the new standard of care: Ziihera + tislelizumab as foundational backbone for HER2+ mGEA, **independent of PD-L1 status**

2. Accelerated Market Access

Leveraging immediate reimbursement: Utilize established, permanent J-code eliminating barriers to launch and driving rapid formulary adoption

3. Commercial & Field Execution

Day-one mobilization: cross-functional teams **prepared to launch immediately upon FDA approval**; capitalize on significant account overlap

4. Seamless Patient Experience

Frictionless onboarding: Activating comprehensive **JazzCares support services**; ensure zero barriers to patient access

Modeyso: Strong Initial Uptake and Early Launch Success

1 Disease State Awareness & Education

CNS WHO Grade 4 glioma[1]
The most aggressive form of glioma

Invariably lethal with **rapid mortality**
Median OS: ~1 yr from diagnosis[2-5] and <6 months after recurrence[6]

Limited surgical options and **no approved therapies** for H3 K27M-mutant diffuse midline glioma[7,8]

2 Branded Campaign Launch



First and **only** FDA-approved treatment for recurrent H3 K27M-mutant diffuse midline glioma

3 Launch Exceeding Expectations

Strong HCP awareness and focus on testing driving increasing breadth of adoption

Strong engagement with community oncologists; >600 patients have received Modeyso[9]

$48M in 2Q26 net product sales
$500M+ in U.S. peak sales potential

[1]Louis DN et al. Neuro Oncol. 2021;23(8):1231–1251; [2]Zheng L et al. Am J Surg Pathol. 2022;26:863-871; [3]Vuong et al, Frontiers in Oncology March 2022; [4]Mackay A et al. Cancer Cell. 2017;32(4):520-537; [5]Ostrom QT et al. Neuro Oncol. 2023;25:799-807; [6]Bagley et al Cancers 2025, 17(13), 2107; [7]Nabors B et al. Neuro Oncol 25(12), 2114–2116, 2023; [8]Gajjar A et al. J Natl Compr Canc Netw 2025;23(3):113–130; [9]As of June 30, 2026.

Zepzelca: Focused on 1LM ES-SCLC

+42% YoY
(Driven by 1LM uptake)



ZEPZELCA® (lurbinectedin) for injection 4 mg

FDA approved Zepzelca in combination with Tecentriq as first-line maintenance therapy for ES-SCLC in 4Q25

- Growth driven by **uptake in the 1LM setting**
- Opportunity to **redefine the treatment paradigm** in 1L maintenance
- Included in **NCCN Guidelines** as a **Category 1 preferred regimen**
- **Addresses significant unmet need**: IMforte trial results[1] showed mOS of **13.2 months** vs 10.6 months for atezolizumab alone from the point of randomization
- Potential to **increase duration of therapy** with earlier line patients

2026 Dynamics:

- Commercial efforts focused on 1LM ES-SCLC
- Based on the Phase 3 LAGOON trial results, in alignment with the FDA, in 3Q26 the company will submit a labeling supplement to remove the 2L indication
- 1LM indication will not be affected

[1]IMforte data presented at ASCO 2025, IMforte study done in collaboration with F. Hoffmann-La Roche Ltd.

Research & Development

Robert Iannone, M.D., M.S.C.E.
Executive Vice President,
Global Head of Research & Development,
Chief Medical Officer

Jazz Pharmaceuticals

Progress Towards Realizing Full Potential of Zanidatamab

Results from the Phase 3 HERIZON-GEA-01 Study



Data Support Zanidatamab as the HER2-targeted Agent of Choice in 1L HER2+ GEA

- Zanidatamab + tislelizumab provide **benefit regardless of PD-L1 status with 26.4m mOS (+7 months vs. control arm)**
- Submitted data for potential **NCCN Guideline** inclusion
- Data **published in *The New England Journal of Medicine*[1]**
- **Ready for launch** in 1L GEA; PDUFA date of August 25, 2026

Focused on maximizing value of zanidatamab:

- GEA data **de-risks opportunities** across HER2+ indications, including ongoing Ph3 trial in metastatic breast cancer
- Goal to become the **HER2-targeted therapy of choice** and **cornerstone of future growth** for Jazz

Note: Graphical data as presented from the HERIZON-GEA-01 trial by Elimova et.al ASCO GI 2026 [1]Shitara et al., The New England Journal of Medicine, May 2026.

Key Pipeline Programs

Key Clinical Programs	PHASE 1 / PHASE 2 / PHASE 3 / PHASE 4 / REGULATORY	Recent / Upcoming Milestones
Zanidatamab	1L GEA (HERIZON-GEA-01)	Interim OS data expected 3Q26; **PDUFA date of August 25, 2026**
	1L BTC (HERIZON-BTC-302)	
	Breast cancer patients post T-DXd (EmpowHER-BC-303)	Anticipate **top-line data** late 2027 / early 2028
	Neoadjuvant and adjuvant BC (EmpowHER-BC-208)	
	Neoadjuvant treatment of locally advanced BC (I-SPY2)	
	Pivotal trial for HER2+ solid tumors (DiscovHER-Pan-206)	
Dordaviprone	1L H3 K27M-mutant diffuse glioma (ACTION)	Anticipate **interim OS data** in 1H27
JZP3507 (ONC206)	Advanced Pheochromocytoma and Paraganglioma (PCPG)	
	Meningioma	
JZP815	RAF & RAS mutant tumors	
JZP898	Solid tumors	
Epidiolex (cannabidiol oral solution)	Focal-onset seizures	
	Developmental and epileptic encephalopathy (DEE)	**New trial**
	Adults with Lennox-Gastaut syndrome (LGS)[2]	**New trial**
Cannabidiol capsule formulation	Juvenile myoclonic epilepsy (JME)[1]	**New trial**
	Capsule formulation	**NDA submitted**
JZP047	Absence Epilepsy	**Initiated Phase 1** in healthy participants

[1]Phase 2/3 trial utilizing cannabidiol capsule formulation; [2]Phase 3b/4 trial.

Financial Performance

Phil Johnson
Executive Vice President,
Chief Financial Officer

Jazz Pharmaceuticals

2Q26 Financial Results

Continued Commercial Execution + Financial Discipline

	2Q26	2Q25	Key Commentary
Total Revenues	$1,208.3M	$1,045.7M	• 16% increase primarily driven by higher Xywav, Modeyso, Epidiolex, and Zepzelca revenues
Non-GAAP Gross Margin[1]	92.1%	92.7%	• Slight decrease primarily due to royalties on Zepzelca and Modeyso
Non-GAAP SG&A[1]	$343.2M	$310.3M	• 11% increase driven by investments in Modeyso and zanidatamab 1L GEA as well as in building key commercial capabilities
Non-GAAP R&D[1]	$184.9M	$167.0M	• 11% increase driven by higher clinical study costs, primarily related to zanidatamab
Non-GAAP Effective Tax Rate[1]	15.8%	(9.1)%	• 2Q26 reflects changes in expected geographic mix of income and expenses; 2Q25 includes impact of Chimerix Acquisition
Weighted-Average Diluted Shares	69.4M	61.2M	• Increase includes accounting effect of higher stock price on employee stock compensation plans and convertible notes
Non-GAAP EPS/LPS[1]	$5.71	$(8.25)	• Includes acquired IPR&D charges of $0.94 and $14.75 per share in 2Q26 and 2Q25, respectively

[1]Non-GAAP Adjusted Gross margin, SG&A expenses, R&D expenses, ETR, and EPS/LPS are non-GAAP financial measures; for further information see "Non-GAAP Financial Measures“ and reconciliation table in the Appendix.

2026 Financial Guidance

Raising Revenue and Updating Expense Guidance[1]

	Updated 2026 Guidance (as of August 3, 2026)	Prior Guidance (as of May 5, 2026)	Key Commentary
Total Revenues	**$4.60 - $4.75B**	$4.25 - $4.50B	• Continue to expect double-digit growth for combined rare oncology + epilepsy revenue • Now expect double-digit growth for Xywav sales • Now expect $2.025B - $2.125B in rare sleep revenue[2]
Non-GAAP Gross Margin[3]	**90% - 91%**	90% - 91%	
Non-GAAP SG&A[3]	**$1.33 - $1.37B**	$1.26 - $1.32B	• Updated guidance reflects targeted investments to drive further growth of Xywav and Epidiolex and to build key capabilities • Reduction from prior year due to 2025 legal settlements
Non-GAAP R&D[3]	**$725 - $775M**	$725 - $775M	
Non-GAAP Effective Tax Rate[3]	**11.5% - 13.5%**	11.5% - 13.5%	
Weighted-Average Diluted Shares	**69 - 70M**	66 – 67M	• Increase vs 2025 and prior guidance primarily driven by the effect of higher stock price on convertible notes and employee stock compensation plans

[1]Guidance provided by Jazz Pharmaceuticals as of August 3, 2026; [2]Rare sleep franchise includes Xywav, Xyrem and high-sodium oxybate AG royalty revenues; [3]Non-GAAP Adjusted Gross margin, SG&A expenses, R&D expenses, and ETR are non-GAAP financial measures; for further information see "Non-GAAP Financial Measures" and reconciliation table in the Appendix.

Closing

Renee Gala
President and Chief Executive Officer

Strong Momentum Into 2H26

Research and Development

Zanidatamab

Published HERIZON-GEA-01 data in ***The New England Journal of Medicine***[1]

Ready for launch in 1L GEA;
PDUFA date of August 25, 2026

Expect EmpowHER-BC-303 trial top-line readout **late 2027 / early 2028**

Dordaviprone

Expect Phase 3 1L ACTION trial readout **1H27**

Commercial

Epidiolex® (cannabidiol) xywav™

Continued **commercial execution** and data generation

MODEYSO™ (dordaviprone) capsules 125 mg

Strong initial launch with **full-year of commercial sales** in 2026

ZEPZELCA™ (lurbinectedin)

Focused efforts in 1LM ES-SCLC with **full-year of commercial sales**[2] in 2026

Corporate Development

Identifying and **pursuing** opportunities in **Rare Disease** to drive long-term growth and value

[1]Shitara et al., The New England Journal of Medicine, May 2026; [2]Zepzelca in combination with Tecentriq (atezolizumab).

Appendix

Glossary

Acronym	Definition
1L	First-line
1LM	First-line maintenance
2L	Second-line
AG	Authorized generic
ANI	Adjusted net income
ANL	Adjusted net loss
ASCO	American Society of Clinical Oncology
ASCO GI	ASCO Gastrointestinal Cancers Symposium
B	Billion
BC	Breast cancer
BTC	Biliary tract cancer
BTD	Breakthrough Therapy designation
CNS	Central nervous system
DEE	Developmental and epileptic encephalopathy
DS	Dravet syndrome
EC	European Commission
EPS	Earnings per share
ES	Extensive-stage
ETR	Effective tax rate
FDA	U.S. Food and Drug Administration
GAAP	Generally accepted accounting principles
GEA	Gastroesophageal adenocarcinoma
HCP	Healthcare provider
HER2	Human epidermal growth factor receptor 2
HR	Hormone receptor

Acronym	Definition
IH	Idiopathic hypersomnia
JME	Juvenile myoclonic epilepsy
LGS	Lennox-Gastaut Syndrome
LPS	Loss per share
M	Million
mOS	Median overall survival
NCCN	National Comprehensive Cancer Network
NDA	New drug application
NSCLC	Non-small cell lung caner
OS	Overall survival
PCPG	Pheochromocytoma and Paraganglioma
PD-L1	Programmed death ligand 1
PDUFA	Prescription Drug User Fee Act
Ph 2 / 3	Phase 2 / 3 clinical trial
R&D	Research and development
SCLC	Small-cell lung cancer
SG&A	Selling, general and administrative
TCE	T-cell engager
T-DXd	Trastuzumab deruxtecan
TKI	Tyrosine kinase inhibitor
TSC	Tuberous sclerosis complex
WHO	World Health Organization
YTD	Year-to-date through June 30, 2026
YoY	Year-over-year

Reconciliation of GAAP Reported to Non-GAAP Adjusted Information[1]

In millions, except per share amounts (unaudited)	Three Months Ended June 30, 2026		2025	
	Net Income	Diluted EPS	Net Loss	Diluted LPS
GAAP reported	**$192.8**	**$2.78**	**$(718.5)**	**$(11.74)**
Intangible asset amortization	170.0	2.45	162.1	2.65
Share-based compensation expense	73.3	1.06	64.5	1.05
Acquisition accounting inventory fair value step-up	16.6	0.24	37.1	0.61
Integration related expenses[2]	—	—	9.4	0.15
Income tax effect of above adjustments	(56.3)	(0.82)	(59.4)	(0.97)
Non-GAAP adjusted[1]	$396.4	$5.71	$(504.8)	$(8.25)
Weighted-average ordinary shares used in diluted per share calculations – GAAP and non-GAAP[1]	69.4		61.2	

[1]Non-GAAP Adjusted net income (loss) (and the related per share measure) are non-GAAP financial measures; for further information, see "Non-GAAP Financial Measures"; [2]Integration related expenses with respect to the Chimerix Acquisition.

Reconciliation of GAAP Reported to Non-GAAP Adjusted Information[1]

(In millions, except percentages)	Three Months Ended June 30, 2026	2025
GAAP gross margin on total revenues	**90.4 %**	**88.9 %**
Acquisition accounting inventory fair value step-up	1.3 %	3.5 %
Share-based compensation expense	0.4 %	0.3 %
Non-GAAP gross margin on total revenues[1]	92.1 %	92.7 %
GAAP SG&A expenses	**$389.2**	**$358.4**
Share-based compensation expense	(46.0)	(41.0)
Integration related expenses[2]	—	(7.1)
Non-GAAP SG&A expenses[1]	$343.2	$310.3
GAAP R&D expenses	**$207.5**	**$189.9**
Share-based compensation expense	(22.6)	(20.6)
Integration related expenses[2]	—	(2.3)
Non-GAAP R&D expenses[1]	$184.9	$167.0
GAAP ETR	**8.6 %**	**2.3 %**
Income tax effect of GAAP to non-GAAP reconciling items	7.2 %	(11.4)%
Non-GAAP ETR[1]	15.8 %	(9.1)%

[1]Non-GAAP Adjusted Gross Margin, SG&A expenses, R&D expenses and ETR are non-GAAP financial measures; for further information, see "Non-GAAP Financial Measures"; [2]Integration related expenses with respect to the Chimerix Acquisition.

Reconciliation of GAAP to Non-GAAP Adjusted[1] 2026 Guidance

(In millions, except percentages)	Projected Range	
	Low	High
GAAP gross margin on total revenues	**89 %**	**90 %**
Acquisition accounting inventory fair value step-up	1 %	1 %
Non-GAAP gross margin on total revenues[1]	90 %	91 %
GAAP SG&A expenses	**$1,506**	**$1,556**
Share-based compensation expense	(176)	(186)
Non-GAAP SG&A expenses[1]	$1,330	$1,370
GAAP R&D expenses	**$818**	**$873**
Share-based compensation expense	(93)	(98)
Non-GAAP R&D expenses[1]	$725	$775
GAAP ETR	**0 %**	**10 %**
Income tax effect of GAAP to non-GAAP reconciling items	11.5 %	3.5 %
Non-GAAP ETR[1]	11.5 %	13.5 %

[1]Non-GAAP Adjusted Gross Margin, SG&A expenses, R&D expenses and ETR are non-GAAP financial measures; for further information, see “Non-GAAP Financial Measures".